TGTX Q1 2023 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+287.1% YoY

Gross Profit

$7M89.0% margin

Operating Income

-$37M-474.1% margin

Net Income

-$39M-502.8% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+9653.8%

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$60M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$197M

Total Liabilities

$170M

Stockholders' Equity

$27M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$2M	+287.1%
Gross Profit	$7M	$2M	+290.4%
Operating Income	-$37M	-$67M	+44.7%
Net Income	-$39M	-$69M	+43.2%

Revenue Segments

Product revenue, net

$8M100%

License revenue

$38,0000%